



Michael K Schultz, Ph.D.

Title: Founder and Chief Science Officer, Associate Professor

Institutions: Viewpoint Molecular Targeting, Inc. and University of Iowa

LinkedIn: <https://www.linkedin.com/in/michael-schultz-8252b2177>

Biosketch:

Michael K Schultz Ph.D. is a funded NIH investigator, Founder and Chief Science Officer of Viewpoint Molecular Targeting, Inc., and a tenured Associate Professor of Radiology, Pediatrics, Free Radical and Radiation Biology, and Chemistry at the University of Iowa. Dr. Schultz has been involved in NETs research and the development of new imaging and therapy agents for NETs for over 15 years and has been a Project Leader in the NETs Specialized Program of Research Excellence (SPoRE) team at the University of Iowa since 2015. His expertise is cancer radiopharmaceutical sciences, radiochemistry, radiation biology, cancer oxidative metabolism and drug resistance, and bioconjugate chemistry with a focus on receptor targeted imaging-guided alpha-particle therapy for cancer. His recent publications demonstrate the potential for alpha-particle targeted radionuclide therapy; dosimetry of ^{212}Pb based peptides; production of $^{203}\text{Pb}/^{212}\text{Pb}$ radiopharmaceuticals; ligand design; and generator produced radionuclides. Professor Schultz serves as Co-Investigator on a current NCI R01 project to conduct a Phase I clinical trial of image-guided $^{203}\text{Pb}/^{212}\text{Pb}$ therapy for NET (R01CA243014). Dr. Schultz is also an academic entrepreneur and his company, and together with Viewpoint Co-founder Frances Johnson MD, Dr. Schultz has secured approximately \$14M in peer-reviewed NCI Small Business Innovation Research grants and contracts and approximately \$20M in private capital investment to advance $^{203}\text{Pb}/^{212}\text{Pb}$ image-guided radionuclide therapy for NETs to global availability. The company has secured safe to proceed designations for two imaging trials and two therapeutic trials for its ^{203}Pb imaged-guided ^{212}Pb alpha particle therapy for metastatic melanoma and NETs and has recently received Fastrack designation by the US FDA for its alpha particle therapy for NETs.